ClinicalTrials.gg
CompletedNCT01062113Updated Feb 2, 2021Results posted

Study To Evaluate Efficacy And Safety Of An Additional Dose Of Celecoxib (YM177) In Patients With Post-Tooth Extraction Pain

A Phase 2 interventional study of Celecoxib and Celecoxib in Pain, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 22 sites in Japan. Open to participants aged 20 Years to 64 Years. Per ClinicalTrials.gov, last updated 2021-02-02.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
255
Allocation
Randomized
Ages
20 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies testing celecoxib in Pain — none open to participants now, 1 under way, none of them phase 3. Celecoxib · Pain.

Enrollment
3rd of 22
255 · median 79
Started
2010
with 1 other
Phase 2
5 of 22
none open now
Registered
9th of 22
by date
Lead sponsor
4 of 22
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 22 studies testing celecoxib in Pain, this one is the 3rd largest by enrollment, is one of 2 that started in 2010, is one of 5 in phase 2, and was the 9th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,651 are open to participants now.

Browse Pain studies →

Open to participants now

None of the 22 studies testing celecoxib in Pain is open now. The open studies under Pain, anywhere →

About celecoxib

Celecoxib: first FDA approval 1998 (CELEBREX), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 928 Pain studies recruiting now, 383 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 222 take healthy volunteers.

This study: 20 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 22 studies testing celecoxib in Pain as a file.
02

Study summary

To evaluate efficacy and safety of additional dose of celecoxib, as compared to placebo, in patients with post lateral mandibular impacted third molar tooth extraction pain.

03

Conditions studied

  • Pain

Browse trials for

Keywords

  • Acute pain after oral surgery lateral mandibular Impacted third molar tooth extraction
04

Who can participate

Ages eligible
20 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Initial dose:

  • 20 to 64 years
  • Patients with undergoing mandibular impacted third molar tooth extraction accompanied by lateral bone removal and crown cutting
  • Patients with pain that meets both of the following criteria
  • Pain intensity (4-categorical): "moderate pain" or "severe pain"
  • Pain intensity (VAS): 45.0 mm or more

Additional dose:

  • Patients with pain that corresponds to "4. Agree" or "5. Strongly agree" as the answer to the "question about the pain intensity" during the period from 5 hours to 12 hours post-initial dose of the study drug

Exclusion criteria

Exclusion Criteria:

  • Patients with acute inflammatory findings in the oral cavity necessitating treatment
  • Patients who are scheduled to receive general anesthesia and analgesics in the process of the eligible tooth extraction
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
255 participants (actual)

Study arms

  • Experimental
    Celecoxib 400mg

    Drug: Celecoxib

  • Experimental
    Celecoxib 200mg

    Drug: Celecoxib

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Initial dose: Celecoxib 200mg tablet x 2 will be administrated during a period from 1 to 2 hours post lateral mandibular impacted third molar tooth extraction in subjects with "moderate pain" or "severe pain"rated as 45.0 mm or more on the VAS

  • Additional dose: Celecoxib 200mg tablet x 1 will be administrated during a period from 5 to 12 hours post-initial dose of Celecoxib 400mg in subjects who require an additional analgesic dose for any pain

  • DrugPlacebo

    Additional dose: Placebo (tablet) will be administrated during a period from 5 to 12 hours post-initial dose of Celecoxib 400mg in subjects who require an additional analgesic dose for any pain

06

What researchers measure

Primary outcomes

  1. Efficacy Rate (Percentage) of Patient's Impression

    Patient's impression was assessed by self-report and was entered in the patient diary, based on the following categories: "Excellent", " Good", "Fair" and "Poor". Efficacy rate was calculated from the following formula, "The number of participants assessed as Excellent or Good" over "total participants" multiplied by 100.

    Time frame: 2 hours post-additional dose

Secondary outcomes

  1. Number of Participants in Each Pain Intensity (PI) With 4 Categories

    Pain intensity was entered in the patient diary on the following categories: "No pain", "Mild pain", "Moderate pain" and "Severe pain".

    Time frame: 2 hours after additional dose

  2. Pain Intensity Measured by Visual Analog Scale (VAS)

    The Pain intensity was recorded on the 100 mm VAS in the patient diary, where 0 mm=no pain, 100 mm=unbearable maximal pain.

    Time frame: 2 hours post-additional dose

  3. Differences in Pain Intensity (PI) Measured by VAS Among Participants

    The differences in PI were obtained by subtracting the PI at each time point from the Baseline PI score.

    Time frame: Pre-additional dose (baseline) and 2 hours post-additional dose

07

Results

Posted Nov 19, 2012

Participant flow

Participant flow — Overall Study
MilestoneInitial Dose Celecoxib 400 mgAdditional Dose Celecoxib 200 mgAdditional Dose Placebo
Started1336458
Completed934227
Not completed402231
Withdrew: Adverse event100
Withdrew: Lack of efficacy382231
Withdrew: Withdrawal by subject100

Outcome measures

PrimaryEfficacy Rate (Percentage) of Patient's Impression

Patient's impression was assessed by self-report and was entered in the patient diary, based on the following categories: "Excellent", " Good", "Fair" and "Poor". Efficacy rate was calculated from the following formula, "The number of participants assessed as Excellent or Good" over "total participants" multiplied by 100.

Time frame:
2 hours post-additional dose
Reported as:
Number · percentage of participants
Efficacy Rate (Percentage) of Patient's Impression
percentage of participantsAdditional Dose Celecoxib 200 mgAdditional Dose Placebo
Efficacy Rate (Percentage) of Patient's Impression64.125.9
Statistical analysis
  • Additional Dose Celecoxib 200 mg vs Additional Dose Placebo · asymptotic z-test · p = <0.0001 (The difference in the efficacy rates was tested using normal distribution at a significance level of 2-sided 5%. 2-sided 95% confidence interval (CI) for the difference in the efficacy rates was calculated using normal approximation.) · Risk difference (rd): 38.2 · 95% CI 20.3 to 56.1
SecondaryNumber of Participants in Each Pain Intensity (PI) With 4 Categories

Pain intensity was entered in the patient diary on the following categories: "No pain", "Mild pain", "Moderate pain" and "Severe pain".

Time frame:
2 hours after additional dose
Reported as:
Number · participants
Number of Participants in Each Pain Intensity (PI) With 4 Categories
participantsAdditional Dose Celecoxib 200mgAdditional Dose Placebo
None113
Mild3424
Moderate1828
Severe13
SecondaryPain Intensity Measured by Visual Analog Scale (VAS)

The Pain intensity was recorded on the 100 mm VAS in the patient diary, where 0 mm=no pain, 100 mm=unbearable maximal pain.

Time frame:
2 hours post-additional dose
Reported as:
Mean · mm
Pain Intensity Measured by Visual Analog Scale (VAS)
mmAdditional Dose Celecoxib 200 mgAdditional Dose Placebo
Pain Intensity Measured by Visual Analog Scale (VAS)35.8 ± 25.551.9 ± 21.9
Statistical analysis
  • Additional Dose Celecoxib 200 mg vs Additional Dose Placebo · t-test, 2 sided · p = 0.0003
SecondaryDifferences in Pain Intensity (PI) Measured by VAS Among Participants

The differences in PI were obtained by subtracting the PI at each time point from the Baseline PI score.

Time frame:
Pre-additional dose (baseline) and 2 hours post-additional dose
Reported as:
Mean · mm
Differences in Pain Intensity (PI) Measured by VAS Among Participants
mmAdditional Dose Celecoxib 200 mgAdditional Dose Placebo
Differences in Pain Intensity (PI) Measured by VAS Among Participants33.4 ± 24.212.3 ± 19.5
Statistical analysis
  • Additional Dose Celecoxib 200 mg vs Additional Dose Placebo · t-test, 2 sided · p = <0.0001

Adverse events

Collected over From informed consent to Day 28 postdose. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Initial Dose Celecoxib 400 mg—0/133 (0%)25/133 (18.8%)
Additional Dose Celecoxib 200 mg—0/64 (0%)13/64 (20.3%)
Additional Dose Placebo—0/58 (0%)18/58 (31%)
Most frequent other events
Showing 10 of 18
Most frequent other events
EventInitial Dose Celecoxib 400 mgAdditional Dose Celecoxib 200 mgAdditional Dose Placebo
Beta 2 microglobulin increasedInvestigations7/1335/649/58
Beta-N-acetyl-D-glucosaminidase increasedInvestigations4/1331/645/58
Blood bilirubin increasedInvestigations4/1333/641/58
Blood phosphorus increasedInvestigations0/1330/642/58
White blood cell count increasedInvestigations1/1331/642/58
Blood creatine phosphokinase increasedInvestigations1/1331/641/58
Blood urea increasedInvestigations0/1330/641/58
Protein urine presentInvestigations0/1331/641/58
Urobilin urine presentInvestigations1/1331/641/58
SomnolenceNervous system disorders1/1331/641/58

Baseline characteristics

Age, Customized
Age, Customized(participants)Initial Dose Celecoxib 400 mgAdditional Dose Celecoxib 200 mgAdditional Dose PlaceboTotal
< 18 years0000
Between 18 and 641336458255
>= 65 years0000
Sex: Female, Male
Sex: Female, Male(Participants)Initial Dose Celecoxib 400 mgAdditional Dose Celecoxib 200 mgAdditional Dose PlaceboTotal
Female643936139
Male692522116
08

Study locations

22 sites
  • Jyuzen General Hospital
    Niihama-shi, Ehime, Japan
  • Kyushu Dental College Hospital
    Kitakyusyu-shi, Fukuoka, Japan
  • Bishinkai Medical Corporation Health Park Clinic
    Takasaki-shi, Gunma, Japan
  • Kure Kyosai Hospital
    Kure-shi, Hiroshima, Japan
  • Kanazawa Medical Center
    Kanazawa-shi, Ishikawa, Japan
  • Kagawa University Faculty of Medicine University Hospital
    Kita-gun, Kagawa, Japan
  • Tokai University Hospital
    Isehara-shi, Kanagawa, Japan
  • Kumamoto Medical Center
    Kumamoto-shi, Kumamoto, Japan
  • Sendai Medical Center
    Sendai-shi, Miyagi, Japan
  • Maruko Central General Hospital
    Ueda-shi, Nagano, Japan
  • Nagano National Hospital
    Ueda-shi, Nagano, Japan
  • The Nippon Dental University Niigata Hospital
    Niigata-shi, Niigata, Japan
  • Osaka Dental University Hospital
    Osaka-shi, Osaka, Japan
  • Osaka Prefectural General Medical Center
    Osaka-shi, Osaka, Japan
  • Meikai University Hospital
    Sakado-shi, Saitama, Japan
  • Shizuoka Medical Center
    Sunto-gun, Shizuoka, Japan
  • Tochigi National Hospital
    Utsunomiya-shi, Tochigi, Japan
  • Tokai University Hachioji Hospital
    Hachiouji-shi, Tokyo, Japan
  • Japan Red Cross Musashino Hospital
    Musashino-shi, Tokyo, Japan
  • Showa University Dental Hospital
    Ota-ku, Tokyo, Japan
  • Kanto Medical Center NTT EC
    Shinagawa-ku, Tokyo, Japan
  • Tokyo Medical University Hospital
    Shinjuku-ku, Tokyo, Japan
09

References and documents

Publications

  • Saito K, Kaneko A, Machii K, Ohta H, Ohkura M, Suzuki M. Efficacy and safety of additional 200-mg dose of celecoxib in adult patients with postoperative pain following extraction of impacted third mandibular molar: a multicenter, randomized, double-blind, placebo-controlled, phase II study in Japan. Clin Ther. 2012 Feb;34(2):314-28. doi: 10.1016/j.clinthera.2012.01.004. Epub 2012 Jan 28. PubMed 22284900 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2010, a primary completion of Aug 2010 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2012, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2010
First posted
Feb 4, 2010
Start
Apr 2010
Primary completionActual
Aug 2010
CompletionActual
Aug 2010
Results first posted
Nov 19, 2012
Last update
Feb 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01062113
Responsible party
Sponsor
First posted
Feb 4, 2010
Start date
Apr 2010
Primary completion
Aug 2010
Completion
Aug 2010
Results posted
Nov 19, 2012
Last update
Feb 2, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Celecoxib

Start the discussion